Pharmacogenomics Market - By Offering, By Technology, By Application, By Disease Area, By End Use - Global Forecast, 2025 - 2034

Pharmacogenomics Market Size

The global pharmacogenomics market was estimated at USD 6.6 billion in 2024. The market is expected to grow from USD 7.3 billion in 2025 to USD 17.7 billion in 2034, at a CAGR of 10.4%, according to the latest report published by Global Market Insights Inc. The market growth is driven by the increasing demand for precision medicine along with advancements in various genomic technologies are the primary reasons to stimulate the market.

The increasing requirement for safer and more effective therapies along with individual genetic profiles is encouraging healthcare systems to utilise pharmacogenomic testing in clinical and research settings. Moreover, the expansion of precision medicine programs and integration of genomic data for treatment decisions are driving the adoption of pharmacogenomics solutions.
 

The high burden of chronic diseases, including conditions such as cancer, cardiovascular diseases, infectious diseases and others are becoming more prevalent globally. For instance, WHO mentions over 20 million new cancer cases were reported worldwide in 2022, and according to NIH, 537 million adults were experiencing diabetes in the age group of 20 to 79 years. These trends are pushing healthcare systems to adopt pharmacogenomic testing to improve treatment outcomes and reduce adverse drug reactions. Additionally, the shift toward precision medicine and the integration of genomic data into clinical decision-making are accelerating the adoption of pharmacogenomics solutions.
 

Pharmacogenomics is defined as the study of how an individual's genetic makeup influences their response to drugs, aiming to optimize drug efficacy and minimize adverse effects. It combines pharmacology and genomics to tailor treatments based on genetic variations, supporting personalized medicine by predicting drug responses and guiding dosage decisions.
 

The pharmacogenomics market grew from USD 5 billion in 2021 to USD 6 billion by 2023, registering a CAGR of 10% during this period. This growth was driven by the increasing demand for targeted therapies, rising awareness about adverse drug reactions, and the integration of pharmacogenomic testing into routine clinical care.
 

Pharmacogenomics solutions include sequencing kits, PCR technologies and reagents, microarray platforms, and genotyping services, which are administered across hospitals, academic institutions, pharmaceutical companies, and contract research organizations. Top players in the market include Thermo Fisher Scientific, Illumina, Qiagen, and F. Hoffmann-La Roche Ltd, who offer a wide range of products and services supporting pharmacogenomic testing and analysis. These companies are investing in AI-powered biomarker platforms, companion diagnostics, and bioinformatics tools to expand the eligible patient pool and improve treatment outcomes.
 

The presence of actionable genetic mutations such as CYP2D6, CYP2C19, TPMT, and SLCO1B1 is stimulating demand for targeted therapies and pharmacogenomic panels. These tools are increasingly used in oncology, psychiatry, cardiology, and infectious disease management, contributing to long-term health improvements. Novel platforms for rare variants and drug resistance cases are expanding treatment options and improving prognosis.
 

Moreover, the integration of digital health records, AI-driven clinical decision support systems, and real-world evidence platforms is transforming pharmacogenomics care delivery. Government initiatives and public-private partnerships focused on expanding access to molecular testing and personalized therapies are further supporting market expansion. The growing prevalence of comorbid conditions such as diabetes, mental health disorders, and infectious diseases also contributes to the rising demand for comprehensive pharmacogenomic solutions.
 

Pharmacogenomics Market Trends

• The market is evolving through macro-level shifts in personalized medicine and micro-level advancements in genomic diagnostics, driven by rising chronic disease prevalence and demand for safer, targeted therapies.
   
• Integration of pharmacogenomics into clinical guidelines is standardizing personalized prescribing across therapeutic areas. Also, expansion of pharmacogenomic testing in oncology is improving therapy selection for mutations such as EGFR, KRAS, and BRCA.
   
• Additionally, use of pharmacogenomics in psychiatry is optimizing antidepressant and antipsychotic regimens based on CYP450 variants with growing role in cardiovascular clinical trials and care is guiding statin and anticoagulant therapy through SLCO1B1 and CYP2C9 testing.
   
• Pharmacogenomics is being adopted in infectious disease management to personalize HIV and TB treatments, with development of paediatric and geriatric pharmacogenomic panels is addressing age-specific drug metabolism challenges.
   
• Global initiatives are promoting genomic literacy and clinician training to support broader adoption. Collaborations between pharma companies and diagnostics firms are accelerating companion diagnostic development.
   
• The growing adoption of multi-gene panels and companion diagnostics is enabling personalized treatment strategies, especially for patients with complex conditions and genetic variability.
   
• Challenges in interpreting genetic data and variability in drug response are accelerating the development of AI-powered platforms and bioinformatics tools to support clinical decision-making.
   
• The shift toward integrated care models using pharmacogenomic testing is transforming drug prescribing practices across hospitals, clinics, and research institutions globally.
   
• Digital health platforms and direct-to-consumer genetic testing are expanding access to pharmacogenomic insights, particularly in underserved and tech-enabled regions.
   

Pharmacogenomics Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on offering, the pharmacogenomics market is categorized into products and services. The products segment accounted for 67.1% of the market in 2024 which is driven by the rising demand for genetic testing kits, reagents, and instruments that support personalized therapy decisions across multiple disease areas. The segment is expected to exceed USD 11.7 billion by 2034, growing at a CAGR of 10.3% during the forecast period.
 

• The product segment is further bifurcated into kits and reagents, and instrument and consumables. The kits and reagents segment is further categorized into sequencing kits and reagents, PCR kits and reagents, microarray kits and reagents, and other kits and reagents.
   
• The products segment dominated the market in 2024, driven by the growing demand for genetic testing tools that support personalized treatment decisions across oncology, cardiology, psychiatry, and infectious diseases.
   
• Moreover, the kits and reagents, instruments, and consumables, which are widely adopted in hospitals, research institutions, and diagnostic laboratories, further stimulating the market.
   
• The increasing use of sequencing kits for multi-gene analysis, PCR kits for rapid genotyping, and microarray kits for large-scale screening is stimulating clinical integration. Additionally, advancements in reagent formulations and automation-compatible instruments are improving testing accuracy, throughput, and accessibility.
   
• The services segment is projected to exceed USD 5.9 billion in 2034, driven by the increasing demand for clinical interpretation, bioinformatics support, and personalized therapy recommendations.
   

Based on technology, the pharmacogenomics market is segmented into sequencing, PCR, microarray and other technologies. The sequencing segment dominated the market in 2024 with a market share of 43.5% driven due to its unmatched capability in identifying genetic variations that influence drug response.
 

• The segment sequencing is integrated into clinical workflows, supported by advancements in bioinformatics and decreasing costs of genomic analysis.
   
• The segment plays an important role in uncovering rare variants, pharmacogenetic haplotypes, and polygenic risk scores has made it indispensable for both research and clinical applications. For instance, platforms such as Illumina’s NovaSeq and Thermo Fisher’s Ion Torrent are widely used in pharmacogenomic studies to guide drug selection and dosing.
   
• Moreover, technologies such as next-generation sequencing (NGS) have revolutionized the field by enabling high-throughput, cost-effective, and accurate analysis of entire genomes or targeted gene panels. This has facilitated the development of personalized therapies, especially in oncology, psychiatry, and cardiology, where genetic markers play a critical role in treatment decisions.
   
• The polymerase chain reaction (PCR) remains a widely adopted technology in pharmacogenomics due to its simplicity, speed, and specificity. It is particularly useful for detecting known single nucleotide polymorphisms that influence drug metabolism.
   
• The segment microarray technology plays a niche but valuable role in pharmacogenomics, especially for profiling multiple genetic variants simultaneously. It is commonly used in large-scale population studies and biobanks to assess genetic predispositions to drug response across diverse cohorts.
   

Based on application, the pharmacogenomics market is segmented into personalized medicine, clinical research, drug discovery and preclinical development, and other applications. The personalized medicine segment dominated the market in 2024 with USD 2.6 billion market size, driven by the transformative impact on tailoring treatments to individual genetic profiles.
 

• The growth of personalized medicine is stimulated by the rising requirement and national genomics programs, such as the All of Us Research Program (USA), which integrate pharmacogenomic data into clinical decision-making. According to the Personalized Medicine Coalition, personalized medicines topped one third of new US Food and Drug Administration (FDA) drug approvals for the fourth year in a row in 2023.
   
• Moreover, the increasing availability of companion diagnostics and integration of AI-driven analytics has made personalized medicine more accessible and scalable. Moreover, the FDA has approved pharmacogenomic biomarkers for drug labelling, reinforcing its clinical relevance and regulatory support.
   
• It enables clinicians to optimize drug selection and dosing, reduce adverse drug reactions, and improve therapeutic outcomes across oncology, cardiology, psychiatry, and infectious diseases.
   
• In contrast, clinical research represents a vital application area in pharmacogenomics, driving the discovery of gene-drug interactions and validating biomarkers for therapeutic response. It plays a key role in stratifying patient populations, designing genotype-guided trials, and improving the efficiency of clinical endpoints.
   
• In drug discovery and preclinical development, pharmacogenomics is used to identify novel drug targets, predict toxicity profiles, and assess pharmacokinetics across genetically diverse populations.
   

Based on disease area, the pharmacogenomics market is segmented into oncology, cardiovascular diseases, neurological diseases, infectious diseases, mental health and other disease areas. The oncology segment dominated the market in 2024 with a growing CAGR of 10.7%, the segment domination is stimulated by the high prevalence of cancer and the critical role of genetic profiling in oncology care.
 

• The increasing cases of cancer is the primary reason for the segment growth, according to Wiley, in 2024, there were 20 million new cases globally, with lung, breast, colorectal, and prostate cancers among the most common.
   
• Pharmacogenomics has become important to oncology as it identifies actionable mutations, guide targeted therapies, and reduce adverse drug reactions.
   
• The rise of companion diagnostics, liquid biopsies, and tumour sequencing platforms has accelerated the adoption of pharmacogenomics in cancer care.
   
• A major driver of this segment is the availability of large-scale genomic datasets that support personalized treatment strategies. As reported by Nature, the Cancer Genome Atlas (TCGA), contains data from over 10,000 patients with tumours profiled using whole-exome sequencing, along with treatment histories.
   
• Additionally, neurological diseases, particularly in conditions such as epilepsy, Alzheimer’s disease, and Parkinson’s disease where pharmacogenomics is gaining traction. Genetic variations in drug-metabolizing enzymes can affect the efficacy and safety of antiepileptic drugs.
   
• Whereas, in cardiovascular diseases, pharmacogenomics plays a crucial role in optimizing therapies, with cardiovascular diseases remaining the leading cause of death globally, accounting for over 19.8 million deaths annually, pharmacogenomics is increasingly integrated into cardiology protocols to enhance drug safety and efficacy.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the pharmacogenomics market is categorized into hospitals and clinics, academic and research institutions, pharmaceutical and biotechnology companies, contract research organization (CROs) and other end users. The hospitals and clinics segment is anticipated to reach USD 6.6 billion by 2034, growing with a significant CAGR of 10.2% during the analysis period, driven the increasing integration of genetic testing into routine clinical care.
 

• The healthcare settings are at the forefront of implementing pharmacogenomic protocols for personalized treatment, especially in oncology, cardiology, and psychiatry. The growing adoption of electronic health records (EHRs) with embedded pharmacogenomic decision support tools has enabled clinicians to make informed drug choices based on patient genotypes.
   
• Moreover, hospitals are leading efforts in patient education, clinical trial recruitment, and real-world evidence generation, making them central to the clinical deployment of pharmacogenomics. Their role in early diagnosis, treatment monitoring, and adverse drug reaction mitigation continues to expand as genomic literacy among healthcare professionals improves.
   
• Moreover, contract research organizations (CROs) are the fastest-growing segment in the market, stimulated by the surge in outsourced clinical trials and biomarker-driven drug development. The rise of decentralized trials and real-world data analytics further pushes CRO involvement in pharmacogenomics.
   
• Also, the pharmaceutical and biotechnology companies play a pivotal role in the market by leveraging genetic insights to develop targeted therapies and companion diagnostics.
   

Looking for region specific data?

Download Free PDF

North America Pharmacogenomics Market
 

The North America market dominated the market with a market share of 48.6% in 2024. The market is stimulated by the rising prevalence of chronic diseases, increasing adoption of precision medicine, and growing integration of genomic testing into clinical workflows.
 

• The advancements seen in sequencing technologies, various AI-powered and companion diagnostics, are stimulating personalized treatment approaches across therapeutic areas in countries such as U.S. and Canada.
   
• Hospitals and clinics across North America are adopting and integrating pharmacogenomic panels into routine care, supported by favourable reimbursement policies and clinical guidelines.
   
• The expansion of direct-to-consumer genetic testing is increasing public awareness and access to pharmacogenomic insights, especially for preventive care and wellness applications.
   

The U.S. pharmacogenomics market was valued at USD 2.2 billion and USD 2.4 billion in 2021 and 2022, respectively. The market size reached USD 2.9 billion in 2024, growing from USD 2.7 billion in 2023.
 

• The aging population and rise in polypharmacy are driving demand for pharmacogenomic tools to reduce adverse drug reactions and optimize dosing in elderly patients. According to Population Reference Bureau, in 2022 58 million of people were aged above 65 years old in U.S., stimulating the market demand.
   
• Digital health platforms and EHR integration are enabling seamless access to genomic data, improving prescribing decisions and continuity of care.
   
• AI-powered bioinformatics tools are helping clinicians interpret complex genetic data, reducing trial-and-error prescribing and improving treatment outcomes.
   
• Academic and research institutions in the U.S. are leading innovation in pharmacogenomics, supported by NIH-funded initiatives and public-private partnerships.
   

Europe Pharmacogenomics Market
 

Europe market accounted for USD 1.8 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• European countries such as Germany and France are witnessing rising demand for pharmacogenomic testing, driven by increasing chronic disease prevalence and growing adoption of personalized medicine.
   
• According to NIH, over 85% of deaths in Europe are due to chronic diseases including cancer, cardiovascular disease, chronic respiratory disease, diabetes, and mental illness, driving the need for safer, genetically guided therapies.
   
• Countries such as the UK, Italy, and Spain are strengthening national precision medicine programs, improving access to high cost pharmacogenomic diagnostics and targeted treatments.
   

Germany pharmacogenomics market is anticipated to witness considerable growth over the analysis period.
 

• Germany is leading in clinical integration of pharmacogenomics, with major university hospitals and research centers routinely using genetic testing to guide drug therapy decisions. For instance, the University of Tubingen’s ICEPHA has an initiative for advancing pharmacogenomics through research and clinical integration.
   
• The country has strong regulatory and reimbursement support, with pharmacogenomic tests increasingly covered under statutory health insurance, making personalized medicine more accessible to the general population.
   
• Germany’s biotech ecosystem is driving innovation, with numerous startups and academic collaborations focused on developing AI-powered genomic platforms and expanding pharmacogenomic applications beyond traditional disease areas.
   

Asia Pacific Pharmacogenomics Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 10.8% during the analysis timeframe.
 

• The region consists of key markets including China, India, Japan, South Korea, and Australia, where rising chronic disease cases and expanding healthcare investments are driving demand for personalized, genomics-based therapies.
   
• Additionally, improving healthcare infrastructure and growing middle-class populations are enhancing access to pharmacogenomic testing and targeted treatments. Clinicians and genetic counselors play a vital role in prescribing genotype-guided therapies across oncology, cardiology, and mental health.
   

China pharmacogenomics market is predicted to grow significantly over the forecast period.
 

• The country is experiencing rapid growth in pharmacogenomics adoption, driven by the higher chronic disease prevalence long with strong government investment in precision medicine, as Bayer mentions that the healthcare spending will exceed USD 2.5 trillion by 2035 in China, further driving the market demand.
   
• The availability of AI-powered diagnostic platforms, such as DAMO PANDA for cancer detection, is transforming pharmacogenomic workflows and enabling scalable, non-invasive testing.
   

Latin America Pharmacogenomics Market
 

Brazil is experiencing significant growth in the Latin America market due to the increasing demand for skin treatment solutions and long-term care.
 

• The country has high prevalence of chronic conditions including diabetes and cardiovascular disease are increasing the need for genotype-guided drug therapies, further driving the market demand.
   
• According to NIH, Brazil experiences high cases of adverse drug reactions linked to genetic variability, stimulating demand for pharmacogenomic testing.
   
• Brazil’s universal healthcare system and expanding private sector are enhancing access to pharmacogenomic diagnostics, with hospitals increasingly adopting multi-gene panels for oncology and psychiatry.
   

Middle East and Africa Pharmacogenomics Market
 

Saudi Arabia market is poised to witness substantial growth in Middle East and Africa market during the forecast period.
 

• The market is expanding rapidly due to rising chronic disease rates and increased awareness of personalized medicine, especially in urban centers.
   
• The expansion of genomic research centers and government-backed precision medicine initiatives is boosting clinical integration of pharmacogenomics across therapeutic areas.
   

Pharmacogenomics Market Share

Leading companies such as Thermo Fisher Scientific., Illumina, F. Hoffmann-La Roche, QIAGEN, and Agilent Technologies collectively hold approximately 48% of the global market share. These firms maintain dominance through expansive genomic portfolios, strategic clinical collaborations, regulatory expertise, and continuous innovation in sequencing, PCR, and microarray scanners and technologies.
 

Thermo Fisher Scientific holds a strong competitive advantage with its comprehensive pharmacogenomic solutions, including the PharmacoScan platform and NGS-based companion diagnostics, widely adopted across oncology, psychiatry, and cardiology.
 

Illumina supports global pharmacogenomics with high-throughput sequencing platforms and targeted gene panels, enabling precision diagnostics and biomarker-driven therapies across clinical and research settings.
 

F. Hoffmann-La Roche strengthens its position through integrated diagnostics and personalized medicine programs, offering sequencing technologies and companion diagnostics that align with targeted drug development.
 

QIAGEN has gained market traction with its QIAseq panels and PCR-based genotyping kits, supporting clinical decision-making and expanding its reach in hospital and academic genomics programs.
 

Agilent Technologies leads in microarray and PCR reagent innovation, offering robust platforms for gene expression analysis and pharmacogenomic profiling, backed by strong research collaborations.
 

New entrants and niche players such as Admera Health, OneOme, Genomind, and Genelex are disrupting the market with focused pharmacogenomic panels and AI-powered interpretation tools. Their emphasis on mental health, cardiovascular risk, and consumer genomics positions them as agile competitors in the evolving landscape of personalized medicine. Meanwhile, companies such as 23andMe and Revvity contribute to broader pharmacogenomics categories, supporting expanded access and awareness through direct-to-consumer and clinical channels.
 

Pharmacogenomics Market Companies

Few prominent players operating in the pharmacogenomics industry includes:
 

• 23andMe
• Admera Health
• Agilent Technologies
• Becton, Dickinson and Company
• Bio-Rad Laboratories
• Charles River Laboratories
• Danaher
• Eurofins Scientific
• F. Hoffmann-La Roche
• Genelex
• Genomind
• Illumina
• Laboratory Corporation of America Holdings
• Novogene
• OneOme
• Qiagen
• Revvity
• Takara Bio
• Thermo Fisher Scientific

• Thermo Fisher Scientific

Thermo Fisher leads the pharmacogenomics market with an estimated share of approximately 16.2%, offering a comprehensive portfolio. The company’s strength lies in its integration of sequencing, microarray, and bioinformatics tools, enabling precision diagnostics across oncology, cardiology, and psychiatry. Its global reach, clinical partnerships, and regulatory expertise reinforce its leadership in personalized medicine.
 

• Illumina

Illumina maintains a strong position through its high-throughput sequencing platforms such as NovaSeq and MiSeq, widely used in pharmacogenomic testing and biomarker discovery. The company’s focus on innovation in library prep kits and companion diagnostics supports its presence in both clinical and research settings. Illumina’s strategic collaborations and data-driven approach continue to expand its influence in precision healthcare.
 

• QIAGEN

QIAGEN competes with targeted DNA panels, PCR kits, and integrated bioinformatics solutions like QIAGEN Clinical Insight, supporting genotype-guided therapy decisions. Its emphasis on scalable testing, regulatory compliance, and hospital-based adoption positions it as a key player in clinical pharmacogenomics. QIAGEN’s expanding portfolio and partnerships with pharmaceutical companies enhance its relevance in drug development and personalized care.
 

Pharmacogenomics Industry News

• In September 2025, Quest Diagnostics launched an advanced pharmacogenomics (PGx) laboratory test service in collaboration with Coriell Life Sciences, offering personalized drug response insights across specialties including psychiatry, oncology, cardiology, and pain management.
   
• In March 2025, InformedDNA acquired Coriell Life Sciences to expand its pharmacogenomics capabilities and integrate genetic insights into its precision health platform. The acquisition included Corigen, enhanced InformedDNA’s service portfolio and strengthened its position in personalized medicine and genomic-driven care.
   
• In October 2024, QIAGEN Digital introduced the PGXI knowledgebase, a centralized platform designed to help researchers interpret gene-drug interactions using curated pharmacogenomic data from global sources. This launch expanded its role in precision medicine infrastructure.
   
• In May 2024, Oxford Nanopore Technologies and Twist Bioscience initiated a pharmacogenomics beta program combining long-read sequencing and target enrichment technologies. This collaboration enhanced both companies capabilities in clinical genomics.
   

The pharmacogenomics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Billion from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Offerings

• Products                
  • Kits and reagents    
    • Sequencing kits and reagents
    • PCR kits and reagents
    • Microarray kits and reagents
    • Other kits and reagents
  • Instrument and consumables         
• Services                

Market, By Technology

• Sequencing
• PCR
• Microarray
• Other technologies

Market, By Application

• Personalized medicine
• Clinical research
• Drug discovery and preclinical development
• Other applications

Market, By Disease Area

• Oncology
• Cardiovascular diseases
• Neurological diseases
• Infectious diseases
• Mental health
• Other disease areas

Market, By End Use

• Hospitals and clinics
• Academic and research institutions
• Pharmaceutical and biotechnology companies
• Contract research organization (CROs)
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE